scholarly journals Effects on the Secretion of Pituitary Growth Hormone, Thyroid Stimulating Hormone, Luteinizing Hormone and Follicle Stimulating Hormone in Rats Rendered Hyperprolactinaemic by Chronic Treatment with Oestrogen

1981 ◽  
Vol 34 (3) ◽  
pp. 321 ◽  
Author(s):  
GA Smythe ◽  
JF Brandstater ◽  
RF Vining
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Chronic Administration ◽  
Serum Levels ◽  
Thyroid Stimulating Hormone ◽  
Significant Inhibition ◽  
Male Rat ◽  
High Dose ◽  
Stimulating Hormone

The induction of hyperprolactinaemia in the male rat following chronic high-dose oestrogen administration over 3 months was associated With a significant inhibition of the secretion of growth hormone (OH) (P < 0�02) thyroid stimulating hormone (TSH) (P < 0�0025), luteinizing hormone (LH) and follicle stimulating hormone (FSH) (both P < 0�01). Acute, but not chronic, administration of bromocriptine (1 mg/kg) to these hyperprolactinaemic animals had the effect of normalizing the serum levels of GH and TSH but not those of LH or FSH. While the effects observed on GH, TSH, LH and FSH following induction of hyperprolactinaemia are likely to be consequential to brain actions of prolactin, the present data do not exclude the possibility of direct actions of oestrogen itself.

scholarly journals Short-term effect of Tramadol injection on the serum levels of Follicle Stimulating Hormone, Luteinizing Hormone and Testosterone in Male Sahel Goats in Maiduguri, Nigeria

2019 ◽  
Vol 7 (1) ◽  
pp. 6
Author(s):  
Babagana Bako ◽  
Sani Malami ◽  
Garba Uthman Sadiq ◽  
Lawan Gana Ashiekh
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Serum Levels ◽  
Term Effect ◽  
Control Group ◽  
High Dose ◽  
Short Term ◽  
Short Term Effect ◽  
Group 4 ◽  
Stimulating Hormone

Tramadol is a synthetic analogue of codeine. Its mood elevation property and sex enhancement potentials are the main reason for its abuse. The aim of the study was to determine the short-term effect of tramadol administration on Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Testosterone (TEST) levels in Male Sahel Goats. This was an experimental study conducted from 1st October 2017 to 12th November 2017 at the Livestock Teaching and Research Farm, University of Maiduguri, Maiduguri, Borno State Nigeria involving 20 Male Sahel Goats. The goats were divided in to 4 groups of 5 each; group 1 served as control and groups 2, 3 and 4 were injected intramuscularly with 4 mg/kg (low dose), 8 mg/kg (medium dose) and 12 mg/kg (high dose) of Tramadol respectively. The injections were given intramuscularly, 3 times a week for 4 weeks. Blood samples were collected to determine the serum levels of FSH, LH and TEST at 0, 1 week, 2 weeks, 3 weeks and 4 weeks of tramadol injections. The Mean±SD of the hormones were computed using SPSS 20. The difference in mean was compared using t test and ANOVA with p < 0.05 set for statistical significance. The baseline levels of FSH, LH and TEST in Male Sahel Goat in Maiduguri were 2.91±5.74 Miu/ml, 0.29±0.72 Miu/ml and 3.92±6.39 ng/ml respectively. Only the goats in group 4 showed a significant increase in serum FSH and LH by the 4th week (P=0.01 and 0.03 respectively) while no significant change was noted in the other groups. The was a decline in the level of Testosterone from 1st week through 4th week in all the experimental group but the level in the control group remain fairly constant throughout the experiment. The decline is inversely proportional to the dose of tramadol injection and most marked in group 4.High dose and prolonged used of Tramadol should be avoided because of side effects of Hypergonadotrophic hypogonadism.  

scholarly journals Significance of hyperprolactinemia for cytomorphologic features of breast secretions

2010 ◽  
Vol 67 (1) ◽  
pp. 42-47
Author(s):  
Danijela Radojkovic ◽  
Slobodan Antic ◽  
Milica Pesic ◽  
Milan Radojkovic ◽  
Dijana Basic ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Nipple Discharge ◽  
Thyroid Stimulating Hormone ◽  
Serum Prolactin ◽  
Control Group ◽  
Clinical Group ◽  
Group I ◽  
Stimulating Hormone

Background/Aim. Nipple discharge syndrome is a clinical entity capable of presenting various disorders such is mammary infection (nonpuerperal and puerperal mastitis), intraductal papillomas, fibrodenoma, breast cancer and hyperprolactinemia syndrome. The aim of the study was to determine differencies in cytological features of mammary secretion in patients with hyperprolactinemia and those with normal serum prolactin levels and to define the role of growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone in creating cellular profile of breast secretion. Methods. The study included 50 patients with nipple discharge syndrome. The patients were devided into the clinical group (27 patients with hyperprolactinemia and nipple discharge) and the control group I (23 patients with normal serum prolactin and nipple discharge). The control group II included the patients of the clinical group achiving normalised serum prolactin levels after the treatment of hyperprolactinemia. Serum prolactin, follicle-stimulating hormone and luteinizing hormone levels were assessed by RIA using commercial kits IRMA hPRL, hLH and hFSH, (INEP, Zemun, Serbia) while serum growth hormone and thyroid-stimulating hormone levels were assessed by RIA using commercial kits LKB-wallac. Cytologic evaluation of samples, taken from all the patients with mammary secretion, was done using standard techniques of staining Haemathoxilin-eozine and May- Gr?nwald/Giemsa. Results. Our results showed a significantly higher presence of lipid and protein material in clinical group, in comparison with the control group I (p < 0.01). Also, our data demonstrated significantly higher number of ductal epithelial cells (p < 0.05) and ductal histiocities (p < 0.001) in the clinical group, compared with the control group I. Macrophagies frequency was proportionally higher in clinical group (44.44%) compared the control group I (17.39%). Erythrocites were significantly lower in the clinical group (p < 0.001) than in the control group I. Significantly decreased mammary secretion (p < 0.01), lower lipid (p < 0.01) and protein synthesis (p < 0.01), and less presence of all cellular categories (p < 0.01) were obtained after normalization of serum prolactin levels. Conclusion. Growth hormone, follicle-stimulating hormone, luteinizing hormone and thyroid-stimulating hormone did not show significant influence on creating cytological features of mammary secretion. The most expressive role, hyperprolactinemia demonstrated in the domain of mammary ductal secretory activity, making mammary secretion reach in lipid and protein material and simultaneously increasing number of ductal epithelial cells, ductal histiocytes and 'foam cells'- macrophages. These cytological findings indicate that hyperprolactinemia promote periductal and intraductal steril inflammation which withdraws after serum prolactin normalization.

THE RAT OVARIAN AUGMENTATION METHOD FOR FOLLICLE STIMULATING HORMONE

1972 ◽  
Vol 70 (4) ◽  
pp. 647-653 ◽  
Author(s):  
Peter Christiansen
Keyword(s):  
Growth Hormone ◽  
Luteinizing Hormone ◽  
Urine Sample ◽  
Positive Response ◽  
Follicle Stimulating Hormone ◽  
Human Growth ◽  
Ovarian Response ◽  
Thyroid Stimulating Hormone ◽  
Inert Material ◽  
Stimulating Hormone

ABSTRACT The specificity of the rat ovarian augmentation method (Steelman & Pohley 1953) for follicle stimulation hormone (FSH) has been studied. The addition of luteinizing hormone (LH), thyroid stimulating hormone (TSH), prolactin, ACTH and human growth hormone (GH) did not influence the ovarian response either to ovine or to human FSH. Urine extracts from 2 infants gave no positive response with a dose of one 24 hour urine sample per rat, indicating that inert material in the urine extracts does not influence the ovarian response.

Sign in / Sign up

Export Citation Format

Share Document